INHIBITORS OF DENGUE VIRUS NONSTRUCTURAL PROTEIN 5 NUCLEAR TRAFFICKING AS PROBES OF DENGUE BIOLOGY
Funder
National Health and Medical Research Council
Funding Amount
$741,136.00
Summary
Viral disease is one of the most significant health problems world-wide, making the identification of new therapeutics of critical importance. We aim to characterise in detail novel compounds which inhibit the interaction of the host cell with Dengue virus, and test them in a series of relevant infectious models for Dengue.
Arbovirus Activation And Modulation Of NLRP3 Inflammasome
Funder
National Health and Medical Research Council
Funding Amount
$779,720.00
Summary
This project aims to establish how mosquito borne viruses such as Ross River and dengue viruses interacts with the human host to cause disease, including how the virus evades the host’s immune response to persist and cause disease for prolonged periods. Knowing how differences in the virus and the host’s immune system interplay to cause asymptomatic to severely disabling disease will assist in devising new treatments and prevention programs to lessen the impact of these diseases in Australia.
CLINICAL RESEARCH TO UNDERSTAND ACQUIRED IMMUNITY TO DENGUE VIRUSES
Funder
National Health and Medical Research Council
Funding Amount
$841,953.00
Summary
Dengue, the commonest arboviral disease of humans, is caused by any of the four serotypes of dengue virus (DENV-1-4). This clinical research project will explore how acquired immunity to dengue viruses is expressed. The results will help dengue vaccine developers make better vaccines for use in Australian travellers and in dengue endemic countries in SE Asia.
Roles And Regulation Of Sphingosine Kinase 1 During Dengue Virus Infection
Funder
National Health and Medical Research Council
Funding Amount
$482,795.00
Summary
Dengue virus (DENV) infection is a global human disease with an estimated 50 million infections annually and there is no vaccine or therapy. DENV disease is worsended by the way the body responds to infection and we have investigated these responses. We know the virus changes a molecule in the body called sphingosine-kinase 1 (SK1), which normally controls if cell live or die and how they function. This study will characterise how DENV influences SK1 and if we can target this interaction to deve ....Dengue virus (DENV) infection is a global human disease with an estimated 50 million infections annually and there is no vaccine or therapy. DENV disease is worsended by the way the body responds to infection and we have investigated these responses. We know the virus changes a molecule in the body called sphingosine-kinase 1 (SK1), which normally controls if cell live or die and how they function. This study will characterise how DENV influences SK1 and if we can target this interaction to develop new drugs against DENV infection.Read moreRead less
Flaviviral Proteases As Viable Targets For Antiinfective Drugs
Funder
National Health and Medical Research Council
Funding Amount
$620,716.00
Summary
Viruses hijack the machinery and nutrients of cells they infect in order to reproduce. We will study viral enzymes (proteases) essential for virus replication, use fluorescent probes to learn where the viral enzymes hide and act in infected cells, track the passage of drugs aimed at these enzymes, design drugs to block their actions and stop virus replication, and test antiviral activity against Dengue, West Nile, Japanese Encephalitis and Yellow Fever viruses which infect millions of people.
Chimeric Insect-specific Flaviviruses: A New Generation Of Diagnostics And Vaccines Against Mosquito-borne Viral Disease
Funder
National Health and Medical Research Council
Funding Amount
$549,937.00
Summary
Dengue, Zika and West Nile are mosquito-borne viruses that cause disease outbreaks world-wide. We will develop safe, cheap and authentic diagnostics and vaccines against these diseases based on novel viruses that only infect mosquitoes. This is a timely paradigm shift for vaccine and diagnostic development. This innovative strategy will have high impact in the field of vector-borne viral diseases and provide a blueprint to develop safe diagnostics and vaccines for other mosquito-borne diseases.
microRNAs (miRNAs) constitute a novel mechanism used by cells and viruses to regulate gene expression. Studies carried out in non-human primates demonstrated great potential for miRNA-inhibiting drugs as novel antiviral agents against hepatitis C virus infection. By characterising how miRNAs control the antiviral state, we will gain new insights into how miRNA-modulating drugs could present novel strategies to treat viral infections.
The Dengue Virus Glycoprotein NS1 Binds Cholesterol And Mediates Cellular Activation
Funder
National Health and Medical Research Council
Funding Amount
$632,029.00
Summary
Cholesterol has been shown to play a vital role in the life cycle of many viruses. This project will investigate the basis of dengue virus interaction with this important host molecule and along with investigations of how dengue is able to stimulate host cells, will provide new insights into the way these viruses cause severe disease. Findings from this study will also aid in the development of new drug strategies for dengue and related viruses such as West Nile virus.
Evolutionary Response Of Dengue And Chikungunya Viruses To A Novel Biocontrol Method
Funder
National Health and Medical Research Council
Funding Amount
$421,681.00
Summary
Dengue and chikungunya are mosquito-transmitted viruses that present significant public health threats to Australia and the Asia-Pacific. This project will investigate whether dengue and chikungunya can adapt in response to a bacterium that limits replication of the viruses in the mosquito. The research will provide critical data to inform new mosquito control methods aimed at breaking the virus transmission cycle. More broadly, the research will allow us to understand how viruses adapt to strat ....Dengue and chikungunya are mosquito-transmitted viruses that present significant public health threats to Australia and the Asia-Pacific. This project will investigate whether dengue and chikungunya can adapt in response to a bacterium that limits replication of the viruses in the mosquito. The research will provide critical data to inform new mosquito control methods aimed at breaking the virus transmission cycle. More broadly, the research will allow us to understand how viruses adapt to strategies aimed at limiting their replication.Read moreRead less
The Genetic Basis Of Pathogen Blocking: Elucidating The Contributions Of The Wolbachia, Dengue Virus And Mosquito Genomes
Funder
National Health and Medical Research Council
Funding Amount
$736,339.00
Summary
A bacterium called Wolbachia has been shown to stop dengue virus from replicating inside mosquitoes and so is being field-tested as a biocontrol agent against dengue fever. A major threat to this strategy is the emergence of resistance either in the mosquito or virus. This proposal addresses two fundamental knowledge gaps – how does Wolbachia block virus growth and how might resistance evolve? This research is significant as it will inform the development of strategies to counter resistance.